Stockscreener 앱 받기
0.3713
1.75%
-0.0066
시간 외 거래:
.36
-0.0113
-3.04%
전일 마감가:
$0.3779
열려 있는:
$0.3798
하루 거래량:
632.49K
Relative Volume:
0.74
시가총액:
$22.42M
수익:
$2.29M
순이익/손실:
$-18.63M
주가수익비율:
-0.6608
EPS:
-0.5619
순현금흐름:
$-19.32M
1주 성능:
-9.44%
1개월 성능:
-3.31%
6개월 성능:
-58.28%
1년 성능:
-55.27%
1일 변동 폭
$0.364
$0.3799
1주일 범위
$0.36
$0.3899
52주 변동 폭
$0.3067
$1.11
Femasys Inc Stock (FEMY) Company Profile
명칭
Femasys Inc
전화
770-500-3910
주소
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.3713 | 22.82M | 2.29M | -18.63M | -19.32M | -0.5619 |
ISRG
Intuitive Surgical Inc
|
402.30 | 146.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.43 | 40.04B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.28 | 32.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.19 | 30.23B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
182.82 | 27.04B | 5.54B | 1.52B | 1.74B | 10.37 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | Laidlaw | Buy |
Femasys Inc 주식(FEMY)의 최신 뉴스
FEMY Technical Analysis & Stock Price Forecast - Intellectia AI
Femasys Inc. (FEMY) Edges Higher as Key Support Holds at $0.37Growth Stock Picks - thelegaladvocate.com
FEMY Technical Analysis | Trend, Signals & Chart Patterns | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Femasys Jumps Almost 30% as Nasdaq Deadline Remains - TechStock²
Femasys Inc. (FEMY) Q1 2026 Earnings: EPS Beat Drives 29.85% Stock SurgeEarnings Revision Downgrade - newsline.com
Femasys Analyst Ratings and Price Targets | NASDAQ:FEMY - Benzinga
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter - Sahm
Femasys receives CE Mark approval for FemHSG fertility catheter - Investing.com UK
Femasys updates corporate presentation on women’s health portfolio - TipRanks
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
Femasys posts updated corporate presentation detailing fertility and FemBloc commercialization plans - TradingView
Femasys (NASDAQ: FEMY) outlines FemaSeed fertility and FemBloc birth control strategy - Stock Titan
Femasys receives CE Mark approval for FemHSG fertility catheter By Investing.com - Investing.com South Africa
Lake Street Remains a Buy on Femasys (FEMY) - The Globe and Mail
Femasys Expands Fertility Care Portfolio In Europe With CE Mark Approval For Femhsg™ Catheter - TradingView
TradingKey - TradingKey
Femasys Reverse Stock Split May Not Prevent Nasdaq Delisting Risk, Observer Warns - The Globe and Mail
Femasys Inc. Announces Financial Results for Quarter Ending March 31, 2026 - geneonline.com
Femasys Inc. Q1 2026 Financials: Revenue Growth, Forward-Looking Statements, and Market Strategy - Minichart
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
FEMASYS INC 1Q 2026: Revenue $424.9K, Net income $328.6K, EPS $0— 10-Q Summary - TradingView
Non-cash gains lift Femasys (NASDAQ: FEMY) to Q1 profit amid cash strain - Stock Titan
Net income returns at Femasys (NASDAQ: FEMY) as Q1 2026 results filed - Stock Titan
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - The Manila Times
Femasys starts birth-control trial as it expands fertility care - Stock Titan
Press Release: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - Moomoo
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
FEMY | Femasys Inc. Common Stock Insider Trading - Quiver Quantitative
FEMY News | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Femasys pushes fertility treatment into OB/GYN offices with first paid use - Stock Titan
Femasys Enables OB/GYNs to Deliver First-Line Fertility - GlobeNewswire
MSN Money - MSN
FEMY Earnings History & Surprises | EPS & Revenue Results | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Femasys Shareholders Approve Reverse Split and Financing Plans - The Globe and Mail
Femasys Inc. (NASDAQ: FEMY) sets 2026 meeting, director and auditor votes - Stock Titan
[ARS] FEMASYS INC SEC Filing - Stock Titan
Femasys (NASDAQ: FEMY) wins approval for reverse split, high-dilution notes - Stock Titan
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up - MSN
FEMY Stock Price, Quote & Chart | FEMASYS INC (NASDAQ:FEMY) - ChartMill
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026 - The Manila Times
Femasys aims to bring first-line fertility treatment into OB/GYN offices - Stock Titan
Femasys (FEMY) Stock Jumps on Deal (+0.71%) 2026-04-18Buy Signals - Xã Thanh Hà
Femasys partners with AMI Technologies for Israel market entry By Investing.com - Investing.com India
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio - Sahm
Femasys (FEMY) Forms Partnership with AMI Technologies to Expand Fertility Portfolio - GuruFocus
Femasys Inc (FEMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.16%
자본화:
|
볼륨(24시간):